AoU Research Priorities Use Cases

How can we improve outcomes for men diagnosed with prostate cancer?

Although prostate cancer is the most common cancer among men in the U.S., many men have indolent tumors that are unlikely to cause death in a man’s lifetime. Determining which prostate tumors are likely to lead to death is of critical clinical importance to prevent unnecessary treatment and unwanted side-effects. Understanding factors related to disease etiology and progression and developing risk models is essential for personalized medicine and developing better treatment strategies.

The remaining questions allow you to outline in more detail the information needed to address your research question. The series of questions allow up to five entries. If you have more than five entries, please try to prioritize them and enter the remainder in the final field. When done, click Submit at the bottom. No

Select your required Data Item #1, which is most important to your study. This would be an item that needs to be generated and collected from different sources using various procedures, tools, techniques, assays, etc. If not in the current selection, please enter it in the textbox below. Cancer incidence

By what method will Data Item #1 be obtained? This may Include procedures, tools, techniques, assays, and analytical approaches for the collection, measurement, or analysis of data. If you do not find the required method, you may enter it in the textbox below. Electronic Health Records (EHR)

If you did not find your method for obtaining Data Item #1 in the dropdown selection above, please enter it here. Linkage to cancer registry data and/or follow-up questionnaires (w/ medical chart confirmation) may be useful for complete assertainment

Are there specifications that apply to the method by which Data Item #1 will be obtained, e.g., is the measurement taken once a year, every month, or some other variation? If you do not find your specification in the dropdown, you may enter it in the textbox below. Once per year

If Data Item #2 was not in the dropdown, please enter it here. Pathology information on biopsies, number of cores, tumor grade from any biopsies and prostatectomy, etc...

Method #2 Electronic Health Records (EHR)

Specification #2 Quarterly

If Data Item #3 was not in the dropdown, please enter it here Prostate screening history

Method #3 Electronic Health Records (EHR)

Specification #3 Once per year

Data Item #4 Genome

Method #4 Whole Genome Genotyping (WGG)

Specification #4 Once

If Data Item #5 was not in the dropdown, please enter it here PSA tests; prostate biopsy tissue; tumor blocks

Method #5 Clinical diagnostic tests

Specification #5 At specified times anchored to the clinical event

Voting

1 vote
Ideate
Idea No. 767